| Sandy River Center | |
| 119 Livermore Falls Rd, Farmington, Maine 04938 | |
| (207) 778-6591 | |
| Name | Sandy River Center |
|---|---|
| Location | 119 Livermore Falls Rd, Farmington, Maine |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 62 |
| Occupancy Rate | 92.42% |
| Medicare ID (CCN) | 205069 |
| Legal Business Name | Farmington Operations Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1881756120 |
| Organization Name | FARMINGTON OPERATIONS, LLC |
| Doing Business As | SANDY RIVER CENTER |
| Address | 119 Livermore Falls Rd, Farmington, ME 04938 |
| Phone Number | 207-778-6591 |
News Archive
Canadian researchers have launched the world's first clinical trial of a novel investigational therapy that uses a combination of two viruses to attack and kill cancer cells, and stimulate an anti-cancer immune response. Previous research by this team and others worldwide suggests that this approach could be very powerful, and could have fewer side effects than conventional chemotherapy and radiation, although it will take years to rigorously test through this trial and others.
In a paper published in today's online issue of the Journal of Alzheimer's Disease (DOI 10.3233/JAD-190772), TauRx has reported unexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine on the brain in over 1,000 patients with mild-to-moderate Alzheimer's disease.
Osteoporosis, a common age-related disease, is being investigated by a group of biomechanical engineers at Vienna University of Technology (TU Vienna).
The All of Us Research Program, part of the National Institutes of Health, today announced that it is leveraging its significant and diverse participant base to seek new insights into COVID-19-through antibody testing, a survey on the pandemic's impacts and collection of electronic health record information.
Results of EORTC trial 10853 appearing in the Journal of Clinical Oncology show that breast conserving treatment combined with radiotherapy reduces the risk of local recurrence in women with ductal carcinoma in situ (DCIS).
› Verified 9 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Canadian researchers have launched the world's first clinical trial of a novel investigational therapy that uses a combination of two viruses to attack and kill cancer cells, and stimulate an anti-cancer immune response. Previous research by this team and others worldwide suggests that this approach could be very powerful, and could have fewer side effects than conventional chemotherapy and radiation, although it will take years to rigorously test through this trial and others.
In a paper published in today's online issue of the Journal of Alzheimer's Disease (DOI 10.3233/JAD-190772), TauRx has reported unexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine on the brain in over 1,000 patients with mild-to-moderate Alzheimer's disease.
Osteoporosis, a common age-related disease, is being investigated by a group of biomechanical engineers at Vienna University of Technology (TU Vienna).
The All of Us Research Program, part of the National Institutes of Health, today announced that it is leveraging its significant and diverse participant base to seek new insights into COVID-19-through antibody testing, a survey on the pandemic's impacts and collection of electronic health record information.
Results of EORTC trial 10853 appearing in the Journal of Clinical Oncology show that breast conserving treatment combined with radiotherapy reduces the risk of local recurrence in women with ductal carcinoma in situ (DCIS).
› Verified 9 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $7303 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 22.46 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 6.62 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 75.56 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.31 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.08 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 6.63 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.09 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 95.29 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 10.4 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 57.41 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.35 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 32.64 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 12.68 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 0.64 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.59 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 60.39 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 74.5 | 82.93 |
News Archive
Canadian researchers have launched the world's first clinical trial of a novel investigational therapy that uses a combination of two viruses to attack and kill cancer cells, and stimulate an anti-cancer immune response. Previous research by this team and others worldwide suggests that this approach could be very powerful, and could have fewer side effects than conventional chemotherapy and radiation, although it will take years to rigorously test through this trial and others.
In a paper published in today's online issue of the Journal of Alzheimer's Disease (DOI 10.3233/JAD-190772), TauRx has reported unexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine on the brain in over 1,000 patients with mild-to-moderate Alzheimer's disease.
Osteoporosis, a common age-related disease, is being investigated by a group of biomechanical engineers at Vienna University of Technology (TU Vienna).
The All of Us Research Program, part of the National Institutes of Health, today announced that it is leveraging its significant and diverse participant base to seek new insights into COVID-19-through antibody testing, a survey on the pandemic's impacts and collection of electronic health record information.
Results of EORTC trial 10853 appearing in the Journal of Clinical Oncology show that breast conserving treatment combined with radiotherapy reduces the risk of local recurrence in women with ductal carcinoma in situ (DCIS).
› Verified 9 days ago